{"id":9417,"date":"2026-04-29T14:25:11","date_gmt":"2026-04-29T19:25:11","guid":{"rendered":"https:\/\/fifarma.org\/?post_type=publicaciones&p=9417"},"modified":"2026-04-29T14:26:58","modified_gmt":"2026-04-29T19:26:58","slug":"fifarma-time-to-vax-2025-en","status":"publish","type":"publicaciones","link":"https:\/\/fifarma.org\/en\/publicaciones\/fifarma-time-to-vax-2025-en\/","title":{"rendered":"FIFARMA Time to Vax 2025"},"content":{"rendered":"

The FIFARMA Time to Vax 2025<\/strong>, developed by FIFARMA in collaboration with IQVIA, is the first regional study to analyze access to and availability of innovative vaccines across twelve countries in Latin America. Based on a methodology inspired by the indicator of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the report evaluates 29 vaccines approved globally between 2010 and 2025, examining the time to local approval, levels of public and private availability, and the role of the Pan American Health Organization\u2019s Revolving Fund. The study identifies progress, but also persistent gaps between approval and public coverage, contributing evidence to strengthen timely access to innovative vaccines in the region.<\/p>\n\n\n\n

View document<\/a><\/strong><\/p>\n\n

\n\n\t\t\n
    \n\t\t\t <\/ul>\n <\/div>","protected":false},"author":26,"parent":0,"template":"","ano":[184],"idioma":[45],"etiquetas-publicacion":[57],"categoria-publicacion":[],"class_list":["post-9417","publicaciones","type-publicaciones","status-publish","hentry","ano-184","idioma-english","etiquetas-publicacion-ecosistemas-de-innovacion"],"yoast_head":"\nFIFARMA Time to Vax 2025: Vaccine Access Study in Latin America<\/title>\n<meta name=\"description\" content=\"The FIFARMA Time to Vax 2025 study, developed with IQVIA, analyzes the availability and access to 29 innovative vaccines across 12 countries in Latin America.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025-en\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FIFARMA Time to Vax 2025\" \/>\n<meta property=\"og:description\" content=\"The FIFARMA Time to Vax 2025 study, developed with IQVIA, analyzes the availability and access to 29 innovative vaccines across 12 countries in Latin America.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025-en\/\" \/>\n<meta property=\"og:site_name\" content=\"FIFARMA\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-29T19:26:58+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025-en\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025-en\\\/\",\"name\":\"FIFARMA Time to Vax 2025: Vaccine Access Study in Latin America\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\"},\"datePublished\":\"2026-04-29T19:25:11+00:00\",\"dateModified\":\"2026-04-29T19:26:58+00:00\",\"description\":\"The FIFARMA Time to Vax 2025 study, developed with IQVIA, analyzes the availability and access to 29 innovative vaccines across 12 countries in Latin America.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025-en\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025-en\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/fifarma-time-to-vax-2025-en\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/fifarma.org\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publicaciones\",\"item\":\"https:\\\/\\\/fifarma.org\\\/publicaciones\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"FIFARMA Time to Vax 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#website\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"name\":\"FIFARMA\",\"description\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"publisher\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/fifarma.org\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#organization\",\"name\":\"Fifarma\",\"alternateName\":\"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica\",\"url\":\"https:\\\/\\\/fifarma.org\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"contentUrl\":\"https:\\\/\\\/fifarma.org\\\/wp-content\\\/uploads\\\/2022\\\/10\\\/logo-fifarma.png\",\"width\":195,\"height\":39,\"caption\":\"Fifarma\"},\"image\":{\"@id\":\"https:\\\/\\\/fifarma.org\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FIFARMA Time to Vax 2025: Vaccine Access Study in Latin America","description":"The FIFARMA Time to Vax 2025 study, developed with IQVIA, analyzes the availability and access to 29 innovative vaccines across 12 countries in Latin America.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025-en\/","og_locale":"en_US","og_type":"article","og_title":"FIFARMA Time to Vax 2025","og_description":"The FIFARMA Time to Vax 2025 study, developed with IQVIA, analyzes the availability and access to 29 innovative vaccines across 12 countries in Latin America.","og_url":"https:\/\/fifarma.org\/en\/publications\/fifarma-time-to-vax-2025-en\/","og_site_name":"FIFARMA","article_modified_time":"2026-04-29T19:26:58+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025-en\/","url":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025-en\/","name":"FIFARMA Time to Vax 2025: Vaccine Access Study in Latin America","isPartOf":{"@id":"https:\/\/fifarma.org\/#website"},"datePublished":"2026-04-29T19:25:11+00:00","dateModified":"2026-04-29T19:26:58+00:00","description":"The FIFARMA Time to Vax 2025 study, developed with IQVIA, analyzes the availability and access to 29 innovative vaccines across 12 countries in Latin America.","breadcrumb":{"@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025-en\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025-en\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fifarma.org\/publicaciones\/fifarma-time-to-vax-2025-en\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/fifarma.org\/"},{"@type":"ListItem","position":2,"name":"Publicaciones","item":"https:\/\/fifarma.org\/publicaciones\/"},{"@type":"ListItem","position":3,"name":"FIFARMA Time to Vax 2025"}]},{"@type":"WebSite","@id":"https:\/\/fifarma.org\/#website","url":"https:\/\/fifarma.org\/","name":"FIFARMA","description":"Latin American Federation of the Pharmaceutical Industry","publisher":{"@id":"https:\/\/fifarma.org\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fifarma.org\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fifarma.org\/#organization","name":"Fifarma","alternateName":"Federaci\u00f3n Latinoamericana de la Industria Farmac\u00e9utica","url":"https:\/\/fifarma.org\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/","url":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","contentUrl":"https:\/\/fifarma.org\/wp-content\/uploads\/2022\/10\/logo-fifarma.png","width":195,"height":39,"caption":"Fifarma"},"image":{"@id":"https:\/\/fifarma.org\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones\/9417","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/publicaciones"}],"about":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/types\/publicaciones"}],"author":[{"embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/users\/26"}],"wp:attachment":[{"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/media?parent=9417"}],"wp:term":[{"taxonomy":"ano","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/ano?post=9417"},{"taxonomy":"idioma","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/idioma?post=9417"},{"taxonomy":"etiquetas-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/etiquetas-publicacion?post=9417"},{"taxonomy":"categoria-publicacion","embeddable":true,"href":"https:\/\/fifarma.org\/en\/wp-json\/wp\/v2\/categoria-publicacion?post=9417"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}